$34,880,933

Department of Health and Human Services·Office of Assistant Secretary for Preparedness and Response

to VERICEL CORPORATION

healthactive

WORK BEGAN2026-04-01·LATEST ACTION2026-04-01·SOURCEUSASPENDING·SOURCE IDCONT_AWD_75A50126C00002_7505_-NONE-_-NONE-

Award description

NON SURGICAL DEBRIDEMENT

Verbatim from USAspending.gov. Capitalization, abbreviations, and codes are unchanged.

The Buildout's read

What the model surfaced from this award

Confidence: medium

In plain English

Procurement of non-surgical debridement products from Vericel Corporation for clinical wound care applications.

Sub-sectors

clinical-carewound-care-productsregenerative-medicine

Why this matters

Vericel specializes in advanced cellular therapies and regenerative medicine products; this signals HHS investment in non-invasive wound treatment capabilities.

Supply-chain signal

Large contract indicates HHS stockpiling or sustained procurement of Vericel's debridement products, supporting manufacturing scale and supply chain stability.

U.S.–China competition angle

Regenerative medicine and advanced wound care are competitive biotech sectors; U.S. investment in domestic cellular therapy suppliers reduces reliance on foreign alternatives.

Generated by award_classification v2.0.0 via claude-haiku-4-5-20251001 on 2026-05-15. Cost: $0.002242.

Period of performance

Start

2026-04-01

End

2036-03-31

Status

activein 3604 days

Recipient

VERICEL CORPORATION

UEI WHK8B1525XA7

View full profile →

Sources

USAspending.gov — all awards for this UEI →
SAM.gov entity registration →
Award record ingested from usaspending. Source identifier CONT_AWD_75A50126C00002_7505_-NONE-_-NONE-.

The Buildout does not edit federal records. Any inaccuracy reflects the upstream source; it will update here when corrected there.